Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities
Net income	$ 60,267,491	$ 45,824,328
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	19,303,179	19,075,353
Loss of disposal of property and equipment	41,784
Impairment of goodwill and intangible assets	3,798,866	2,431,791
Provision for doubtful accounts	3,887,647	0
Share-based compensation	1,441,089	2,743,116
Unrealized loss (gain) from investment in equity securities	25,005	(86,005)
Gain on settlement of preexisting note receivable from ApolloMed	0	(921,938)
Gain from investments – fair value adjustments	0	(13,697,018)
Change in fair value of derivative instrument	0	44,886
Loss from equity method investments	8,125,285	1,112,541
Deferred tax	(8,345,235)	(20,675,807)
Changes in operating assets and liabilities, net of acquisition amounts:
Receivable, net	(263,191)	4,108,970
Receivable, net – related parties	(28,363,108)	6,593,783
Prepaid expenses and other current assets	(2,813,564)	1,260,064
Other assets	2,446	(220,925)
Accounts payable and accrued expenses	(22,669,230)	(3,687,022)
Capitation incentives payable	(21,500,000)	1,878,355
Medical liabilities	4,134,209	5,661,313
Income taxes payable	8,423,366	388,138
Net cash provided by operating activities	25,496,039	51,833,923
Cash flows from investing activities
Cash acquired in the Merger	0	37,112,775
Cash received from consolidation of VIE	0	228,287
Purchases of marketable securities	(9,013)	(5,283)
Proceeds from loans receivable	0	200,000
Advances to related parties – loans receivable	(7,500,000)	(10,000,000)
Dividends received from equity method investments	607,411	1,240,000
Proceeds on sale of investments in a privately held entity that does not report net asset value per share	0	25,000
Purchases of investments in a privately held entity that does not report net asset value per share	(405,000)	0
Purchases of investments – equity method	(16,706,152)	0
Purchases of property and equipment	(1,170,064)	(2,084,770)
Net cash (used in) provided by investing activities	(25,182,818)	26,716,009
Cash flows from financing activities
Dividends paid	(17,758,808)	(10,447,923)
Change in noncontrolling interest capital	27,300	0
Borrowings on lines of credit – related party	8,000,000	5,000,000
Advances by NMM to ApolloMed prior to the Merger	0	(9,000,000)
Repayments on bank loan	(495,134)	0
Payment of capital lease obligations	(98,735)	(102,348)
Proceeds from exercise of stock options included in liabilities	0	425,025
Proceeds from exercise of stock options and warrants	3,996,677	164,797
Proceeds from common stock offering	200,000	2,160,736
Repurchase of common shares	(5,047,643)	(3,175,836)
Net cash used in financing activities	(11,176,343)	(14,975,549)
Net (decrease) increase in cash, cash equivalents and restricted cash	(10,863,122)	63,574,383
Cash, cash equivalents and restricted cash, beginning of year	118,500,095	54,925,712
Cash, cash equivalents and restricted cash, end of year	107,636,973	118,500,095
Supplemental disclosures of cash flow information
Cash paid for income taxes	23,642,662	24,362,223
Cash paid for interest	462,336	51,043
Supplemental disclosures of non-cash investing and financing activities
Cashless exercise of stock options	109	0
Deferred tax liability adjusted to goodwill	1,110,456	0
Purchase price adjustment for acceleration of vested stock options	868,000	0
Conversion of loan receivable to investment in Accountable Health Care, IPA	5,000,000	0
Reclassification of dividends related to share repurchase	4,216,202	0
Reclassification of APS noncontrolling interest to equity related to purchase of additional shares	2,832,180	0
Distribution of warrants to former NMM shareholders	0	5,294,000
Issuance of common stock upon conversion of debt and accrued interest	0	5,376,215
Reclassification of liability for unissued common shares payable to equity	0	1,237,650
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents	106,891,503	99,749,199
Restricted cash – long-term - letters of credit	745,470	745,235
Restricted cash – short-term - distributions to former NMM shareholders	0	18,005,661
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	107,636,973	54,925,712
Unvested Stock Compensation [Member]
Supplemental disclosures of non-cash investing and financing activities
Non-cash purchase consideration for acquisition	0	187,333
Preferred Stock [Member]
Supplemental disclosures of non-cash investing and financing activities
Non-cash purchase consideration for acquisition	0	19,118,000
Equity [Member]
Supplemental disclosures of non-cash investing and financing activities
Non-cash purchase consideration for acquisition	0	61,092,050
Network Medical Management, Inc. [Member]
Supplemental disclosures of non-cash investing and financing activities
Non-cash purchase consideration for acquisition	$ 0	$ 5,129,000